43.40
price up icon2.19%   0.93
after-market After Hours: 44.03 0.63 +1.45%
loading
Ultragenyx Pharmaceutical Inc stock is traded at $43.40, with a volume of 431.81K. It is up +2.19% in the last 24 hours and up +2.67% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$42.47
Open:
$42.7
24h Volume:
431.81K
Relative Volume:
0.50
Market Cap:
$4.02B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-6.7079
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
-3.23%
1M Performance:
+2.67%
6M Performance:
-2.93%
1Y Performance:
-3.30%
1-Day Range:
Value
$42.31
$43.91
1-Week Range:
Value
$42.11
$45.27
52-Week Range:
Value
$37.02
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Name
Ultragenyx Pharmaceutical Inc
Name
Phone
415-483-8800
Name
Address
60 LEVERONI COURT, NOVATO, CA
Name
Employee
1,276
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
RARE's Discussions on Twitter

Compare RARE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
43.40 4.02B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.40 113.67B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
683.08 74.97B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.68 40.50B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
277.16 35.95B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
120.88 29.63B 3.30B -501.07M 1.03B -2.1146

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-24 Upgrade Goldman Neutral → Buy
Apr-22-24 Initiated RBC Capital Mkts Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Jun-14-23 Resumed Credit Suisse Outperform
Jun-06-23 Upgrade Evercore ISI In-line → Outperform
Apr-26-23 Initiated Cantor Fitzgerald Overweight
Jan-18-23 Resumed Canaccord Genuity Buy
Dec-30-22 Resumed H.C. Wainwright Buy
Nov-03-22 Upgrade Robert W. Baird Neutral → Outperform
Oct-13-22 Upgrade Guggenheim Neutral → Buy
Aug-01-22 Downgrade Evercore ISI Outperform → In-line
Mar-16-22 Upgrade Credit Suisse Neutral → Outperform
Feb-11-22 Upgrade JP Morgan Neutral → Overweight
Sep-30-21 Initiated H.C. Wainwright Buy
Aug-19-21 Initiated UBS Sell
Jul-15-21 Initiated Guggenheim Neutral
Jun-29-21 Upgrade BofA Securities Neutral → Buy
Jun-04-21 Resumed Robert W. Baird Neutral
May-06-21 Upgrade Citigroup Neutral → Buy
May-06-21 Upgrade Evercore ISI In-line → Outperform
Apr-26-21 Resumed Credit Suisse Neutral
Mar-02-21 Resumed Stifel Buy
Feb-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-07-20 Downgrade Wedbush Outperform → Neutral
Nov-24-20 Resumed Evercore ISI In-line
Nov-12-20 Downgrade BofA Securities Buy → Neutral
Aug-02-19 Resumed Wedbush Outperform
Mar-27-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Feb-22-19 Resumed Raymond James Outperform
Jan-02-19 Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18 Upgrade Citigroup Sell → Neutral
Sep-10-18 Initiated Morgan Stanley Equal-Weight
Jun-21-18 Downgrade Credit Suisse Outperform → Neutral
May-11-18 Upgrade Barclays Equal Weight → Overweight
May-10-18 Initiated Goldman Neutral
Apr-18-18 Upgrade SunTrust Hold → Buy
Mar-22-18 Resumed Piper Jaffray Overweight
Feb-21-18 Reiterated Stifel Buy
Jan-22-18 Upgrade Evercore ISI In-line → Outperform
Jan-18-18 Initiated Credit Suisse Outperform
Dec-05-17 Reiterated Barclays Equal Weight
Dec-04-17 Upgrade Jefferies Hold → Buy
Sep-14-17 Upgrade Wedbush Neutral → Outperform
View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

pulisher
Jan 29, 2025

Ultragenyx Pharmaceutical: Advancing On Multiple Fronts (NASDAQ:RARE) - Seeking Alpha

Jan 29, 2025
pulisher
Jan 28, 2025

Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market - Barchart

Jan 28, 2025
pulisher
Jan 28, 2025

Learn to Evaluate (RARE) using the Charts - Stock Traders Daily

Jan 28, 2025
pulisher
Jan 27, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) adds US$374m to market cap in the past 7 days, though investors from three years ago are still down 37% - Simply Wall St

Jan 27, 2025
pulisher
Jan 27, 2025

What is Wedbush’s Estimate for RARE FY2024 Earnings? - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Wedbush Has Positive Outlook for RARE FY2027 Earnings - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Wedbush Equities Analysts Boost Earnings Estimates for RARE - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Forecasts RARE FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 23, 2025

FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs - Defense World

Jan 23, 2025
pulisher
Jan 23, 2025

Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR

Jan 23, 2025
pulisher
Jan 22, 2025

Ultragenyx's SWOT analysis: rare disease stock poised for growth - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Ultragenyx's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Australia

Jan 22, 2025
pulisher
Jan 22, 2025

Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views - Benzinga

Jan 22, 2025
pulisher
Jan 22, 2025

Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Leerink Partnrs Has Positive Outlook of RARE FY2024 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Predicts RARE FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Assenagon Asset Management S.A. Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Jan 22, 2025
pulisher
Jan 18, 2025

FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 17, 2025
pulisher
Jan 17, 2025

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025
pulisher
Jan 17, 2025

12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025
pulisher
Jan 17, 2025

FY2024 EPS Estimates for RARE Increased by Cantor Fitzgerald - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Hennion & Walsh Asset Management Inc. - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

J.P. Morgan Notebook: Priorities For The Year Ahead - News & Insights

Jan 16, 2025
pulisher
Jan 16, 2025

Wealth Enhancement Advisory Services LLC Acquires 294 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Jan 16, 2025
pulisher
Jan 15, 2025

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - AOL

Jan 15, 2025
pulisher
Jan 15, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 9.1%Here's Why - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $140.00 at Piper Sandler - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Ultragenyx Pharmaceutical’s (RARE) “Neutral” Rating Reaffirmed at Wedbush - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN

Jan 14, 2025
pulisher
Jan 13, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Ultragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at Wedbush - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Ultragenyx stock gains confidence as FY25 guidance signals 14-20% growth By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 13, 2025

Ultragenyx stock gains confidence as FY25 guidance signals 14-20% growth - Investing.com Australia

Jan 13, 2025
pulisher
Jan 13, 2025

JPMorgan Chase & Co. Has $11.84 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for 2024 -January 12, 2025 at 11:00 am EST - Marketscreener.com

Jan 13, 2025
pulisher
Jan 12, 2025

Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewswire

Jan 12, 2025
pulisher
Jan 12, 2025

RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan

Jan 12, 2025
pulisher
Jan 12, 2025

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire

Jan 12, 2025
pulisher
Jan 12, 2025

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones - GlobeNewswire Inc.

Jan 12, 2025
pulisher
Jan 12, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $88.46 Consensus Target Price from Brokerages - Defense World

Jan 12, 2025
pulisher
Jan 09, 2025

Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorder - MSN

Jan 09, 2025
pulisher
Jan 09, 2025

Hypophosphatasia Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma, Alexion - Barchart

Jan 09, 2025
pulisher
Jan 09, 2025

Hypophosphatasia Market Predicted to See Upsurge Through 2032, - openPR

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth - Investing.com Australia

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com South Africa

Jan 09, 2025
pulisher
Jan 09, 2025

Ultragenyx Pharmaceutical’s SWOT analysis: rare disease stock poised for growth - Investing.com Nigeria

Jan 09, 2025
pulisher
Jan 08, 2025

RBC Capital reiterates Outperform rating on Ultragenyx, optimistic on Osteogenesis Imperfecta drug - Investing.com Nigeria

Jan 08, 2025

Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$352.30
price down icon 5.49%
$41.04
price up icon 0.79%
$22.36
price up icon 3.33%
$5.41
price up icon 3.84%
biotechnology ONC
$226.89
price up icon 0.08%
$120.88
price down icon 0.23%
Cap:     |  Volume (24h):